Covance
时间:2016-03-01 12:50:04作者:admin文章来源:Covance浏览:
Covance
上海文乐生物科技有限公司专业代理Covance品牌中国一级代理商
Covance Research Product(CRP),专为生物医学和生物制药学产业提供产品和服务,产品涵盖实验动物、抗体、试剂盒等,尤以神经科学产品见长,同时提供常用的检测用试剂。
Covance Company Overview科文斯公司简介
Covance, with headquarters in Princeton, New Jersey, is one of the worlds largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Offering drug development solutions from preclinical through commercialization, Covance is a world-class provider of the following service lines:
Research products 研究用产品
Antibody products and services抗体的产品和服务
Nonclinical development services非临床开发服务
Risk management services风险管理服务
Clinical pharmacology services临床药理学服务
Central laboratory/Covance local laboratory services中心实验室/科文斯实验室服务
Cardiac safety services 心脏安全服务
Clinical development services 临床开发服务
Commercialization services商业化服务
Covance — Meeting Your Needs
With a commitment to meeting your needs, Covance offers unparalleled expertise, experience and results. Covance knows the significant pressures pharmaceutical and biotechnology companies of all sizes face in developing and launching drugs backed by strong data.
With a business built around your needs, our streamlined approach to drug development means high quality, error-free data designed to help bring your drug to market as quickly, safely and cost effectively as possible, including:
Proving early safety 早期安全证明
Conducting first in human studies
Conducting proof of concept studies
Proving clinical safety and efficacy
Filing for marketing approval
Launching and marketing a drug
Ensuring patient safety and access
Managing risk
Managing over 15,000 clinical trial protocols in 100 countries on 6 continents, Covance provides the experience and exceptional customer service to advance your compound along the drug development continuum. Strategic partnerships built on decades of success — Covance is dedicated to helping bring your miracles to market sooner.